FineMark National Bank & Trust’s United Therapeutics UTHR Stock Holding History

FineMark National Bank & Trust’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-217	Closed	-$23K	–	1424
2016 Q2	$23K	Hold	217	–	–	﹤0.01%	802
2016 Q1	$24K	Hold	217	–	–	﹤0.01%	750
2015 Q4	$34K	Hold	217	–	–	﹤0.01%	709
2015 Q3	$28K	Hold	217	–	–	﹤0.01%	775
2015 Q2	$38K	Hold	217	–	–	0.01%	728
2015 Q1	$37K	Sell	217 -18	-8%	-$2.74K	0.01%	739
2014 Q4	$30K	Sell	235 -54	-19%	-$6.96K	﹤0.01%	810
2014 Q3	$37K	Sell	289 -22	-7%	-$2.27K	0.01%	722
2014 Q2	$28K	Sell	311 -10	-3%	-$962	﹤0.01%	806
2014 Q1	$30K	Sell	321 -181	-36%	-$18.5K	0.01%	764
2013 Q4	$57K	Buy	502 +83	+20%	+$7.49K	0.01%	551
2013 Q3	$33K	Hold	419	–	–	0.01%	665
2013 Q2	$28K	Buy	+419	New	+$27K	0.01%	696

Other funds holding UTHR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FineMark National Bank & Trust's UTHR Position: Q3 2016 in Review

FineMark National Bank & Trust sold out of United Therapeutics (UTHR) in Q3 2016, closing a stake of 217 shares — an estimated $23K sold.

FineMark National Bank & Trust first reported a position in UTHR in Q2 2013 and held it in 13 quarters. The position peaked at $57K in Q4 2013. 394 funds tracked by Wall St. Rank hold UTHR as of Q3 2016.

FineMark National Bank & Trust reported no remaining United Therapeutics position as of Q3 2016 after selling out during the quarter.
FineMark National Bank & Trust sold 217 United Therapeutics shares in Q3 2016, an estimated $23K.
FineMark National Bank & Trust first reported a position in United Therapeutics in Q2 2013 and held it in 13 quarters.
FineMark National Bank & Trust's United Therapeutics position peaked at $57K in Q4 2013.
394 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2016.

Based on FineMark National Bank & Trust's 13F filing for Q3 2016, filed 10 Nov 2016.